Sanofi's Fitusiran Prophylaxis Cuts Bleeds By 61% In Hemophilia Patients

Sanofi SA  (NASDAQ: SNY ) announced data  from the Phase 3 ATLAS-PPX study of once-monthly fitusiran (80 mg) in severe hemophilia A or B patients. The study included previously treated patients with a prior factor or bypassing agent (BPA) prophylaxis. The study met the primary endpoint and demonstrated fitusiran prophylaxis significantly ... Full story available on Benzinga.com